Research programme: stem cell therapies - Promethera Biosciences

Drug Profile

Research programme: stem cell therapies - Promethera Biosciences

Latest Information Update: 27 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Promethera Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency
  • Research Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 21 Apr 2017 Pharmacodynamics data from preclinical studies in Liver disorders presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2017
  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop H2Stem in South Korea
  • 26 Oct 2016 Early research in Fibrosis in Belgium (unspecified route) (Promethera Biosciences pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top